Erlander Mark 4
4 · Cardiff Oncology, Inc. · Filed Mar 7, 2024
Insider Transaction Report
Form 4
Erlander Mark
DirectorChief Executive Officer
Transactions
- Award
Stock Options
2024-03-07+510,000→ 2,170,310 totalExercise: $3.51Exp: 2034-03-07→ Common Stock (510,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.